Novartis AG ADR (NVS)vsPhaos Technology Holdings (Cayman) Limited (POAS)
NVS
Novartis AG ADR
$164.98
-1.85%
HEALTHCARE · Cap: $303.67B
POAS
Phaos Technology Holdings (Cayman) Limited
$0.74
-12.43%
HEALTHCARE · Cap: $2.12M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 43431155% more annual revenue ($57.36B vs $132,080). NVS leads profitability with a 17.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
POAS
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$164.98
$69.42 premium
Intrinsic value data unavailable for POAS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.4x book value
4.7% revenue growth
Grey zone — moderate risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -1073.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : POAS
The strongest argument for POAS centers on Price/Book, Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : POAS
The primary concerns for POAS are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (48/100 vs 23/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Phaos Technology Holdings (Cayman) Limited
HEALTHCARE · MEDICAL DEVICES · USA
Phaos Technology Holdings (Cayman) Limited, through its subsidiary, Phaos Technology Pte. The company is headquartered in Singapore.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?